^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    L105

    i
    Other names: L105, HZ-L105
    Associations

    News

    Trials
    Company:
    Biopolar Hongye (Nantong) Pharma, HealZen Therap
    Drug class:
    Bcl2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    L105, a next generation of Bcl-2 inhibitor, overcomes Bcl-2 mutation and exhibits superior antitumor activity (AACR 2023)
    L105 showed great potency on wild type and acquisition resistance mutations of Bcl-2, excellent oral bioavailability, and superior preclinical anti-tumor activities and safety profiles. It may provide new thoughts on treatment for a wide range of Bcl-2-dependent and Venetoclax-resistant hematological cancers.
    IO biomarker
    |
    BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3)
    |
    BCL2 overexpression • BCL2 mutation • BCL2 G101V
    |
    Venclexta (venetoclax) • L105